

MT2024-06D: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

Status: Recruiting

[Eligibility Criteria](#)

[Conditions & Interventions](#)

More Information

Description: To determine the safety and maximum tolerated dose (MTD) of VCAR33 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) after allogeneic hematopoietic cell transplantation (alloHCT)

Study Contact: Alycia Lape-Krawczynski - lape0021@umn.edu

Principal Investigator: Joseph Maakaron

IRB

Number: STUDY00021822

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.